Brief: Seal Rock Therapeutics Announces Out-Licensing Agreement With Genfit For Development Of Injectable Formulation Of Srt-015 For Acute-On-Chronic Liver Disease

Genfit SA

31/05/2023 22:11

May 31 (Reuters) - Genfit SA  GNFT.PA :
    * SEAL ROCK THERAPEUTICS ANNOUNCES OUT-LICENSING AGREEMENT
WITH
GENFIT FOR DEVELOPMENT OF INJECTABLE FORMULATION OF SRT-015 FOR
ACUTE-ON-CHRONIC LIVER DISEASE (ACLF)
    * SEAL ROCK THERAPEUTICS- ELIGIBLE TO GET PAYMENTS UP TO EUR
100
MILLION, INCLUDING REGULATORY, CLINICAL, COMMERCIAL MILESTONE
PAYMENTS, TIERED ROYALTIES

Source text for Eikon:  ID:nPnz4y03a 
Further company coverage:  GNFT.PA 

 ((Reuters.Briefs@thomsonreuters.com;))